CE Disclosures and Faculty Information

• OVERVIEW OF ACTIVITY
  Taken together, melanoma and nonmelanoma skin cancer — basal cell carcinoma (BCC) and cutaneous squamous cell cancer (SCC) — likely represent the most prevalent form of human cancer. Fortunately, the vast majority of skin cancer presents as minimally invasive BCC and SCC and, as such, is highly curable with local treatment alone. However, in rare instances these characteristically indolent lesions progress and necessitate systemic intervention with the support of limited randomized clinical evidence. In contrast, cancerous melanoma is the most aggressive form of skin cancer, with a predilection toward distant metastases, even when identified in the early stages. Thus melanoma and nonmelanoma skin cancer are distinct entities, each posing unique challenges to the oncology community. Featuring up-to-date information on the latest research developments along with expert perspectives, this CME activity is designed to assist medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES

  • Use biomarkers, clinical characteristics and mutational analyses to select individualized front-line and subsequent treatment approaches for patients with advanced melanoma.
  • Counsel patients regarding the risk of BRAF inhibitor-associated secondary nonmelanoma skin cancers and other adverse events, and implement appropriate surveillance and management strategies.
  • Recall existing and emerging research information demonstrating the impact of combining BRAF and MEK inhibitors for patients with BRAF mutation-positive metastatic melanoma, and use this information to guide treatment planning for these patients.
  • Recognize immune-related adverse events associated with ipilimumab, and offer supportive management strategies to minimize and/or manage these side effects.
  • Appreciate the recent FDA-approved indication for pembrolizumab for patients with metastatic melanoma, and discern how this agent can be optimally integrated into clinical practice.
  • Appraise the rationale for and clinical trial data with investigational anti-PD-1 and anti-PD-L1 antibodies for advanced melanoma.
  • Identify patients with locally advanced or metastatic BCC for whom vismodegib may be an appropriate treatment consideration.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This activity contains an audio component. The participant should listen to the audio MP3s.
  
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-ofthe-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — Dr Margolin had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Daud — Advisory Committee: Amgen Inc, Genentech BioOncology, GlaxoSmithKline, OncoSec Medical; Consulting Agreements: Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, OncoSec Medical; Contracted Research: Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc. Dr Sznol — Advisory Committee: Amphivena Therapeutics Inc, Anaeropharma Science Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Immune Design, Kyowa Hakko Kirin Co Ltd, Lion Biotechnologies, Merus BV, Pfizer Inc, Seattle Genetics, Symphogen A/S; Consulting Agreements: Amphivena Therapeutics Inc, Anaeropharma Science Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Immune Design, Kyowa Hakko Kirin Co Ltd, Lion Biotechnologies, Merck, Merus BV, Pfizer Inc, Seattle Genetics, Symphogen A/S. Dr Hamid — Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Merck; Consulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Pfizer Inc; Contracted Research: Abbott Laboratories, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, MedImmune Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Speakers Bureau: Bristol-Myers Squibb Company, Genentech BioOncology.
  
  EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Genentech BioOncology, Merck, Novartis Pharmaceuticals Corporation and Prometheus Laboratories Inc.
  
  Hardware/Software Requirements:
  A high-speed Internet connection  
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
  Adobe Flash Player 10.2 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio

  Last review date: December 2014
  Expiration date: December 2015